Recent progress in the development of protein–protein interaction inhibitors targeting androgen receptor–coactivator binding in prostate cancer

•New therapeutics are needed to overcome resistance to androgen deprivation therapies.•Castrate-resistant prostate cancer cells are addicted to androgen receptor signaling.•Coactivator recruitment is vital for androgen receptor signaling.•Promising coactivator binding inhibitors have been developed.•These inhibitors retain their activity in castrate-resistant prostate cancer cells.